Adherence to Antipsychotic Drugs by Medication Possession Ratio for Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A Retrospective Cohort Study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Pharmacotherapy is considered as an essential element in the treatment of psychotic disorders including schizophrenia. Discontinuation of antipsychotic drugs increases medical use and economic burden. Therefore, maintenance of medication is essential to reduce the social burden caused by schizophrenia and schizophrenia similar psychosis (SSP), and hence, it is important to investigate the rate at which pharmacotherapy is maintained. Therefore, this study aimed to examine the current status of drug compliance using national health insurance data. Methods: This was a retrospective cohort study, which analyzed data from the nationwide insurance claims database. A total of 343,134 patients who were newly diagnosed with schizophrenia and SSP during 2011−2015. The adherence to antipsychotic drugs was assessed by medication possession ratio (MPR) and the risk factors of poor adherence were defined as MPR ＜ 40%. Results: The average of the MPRs was 45.8%, and the proportion of patients with less than 40% of MPR was 50.8%. It was found that female patients, the experience of “general hospital outpatient,” ““ psychiatric hospital admission,” general hospital admission,” and patients receiving “health insurance” showed high risk of having statistically significant low MPR (＜ 40%). Conclusion: In this study, the drug adherence of schizophrenia and SSP patients currently under treatment, as estimated by MPR, was very low. However, it was also found that the MPR was high among patients receiving medical aid, with less medical expenses. Thus, it is possible to consider an institutional mechanism in which schizophrenia and SSP patients can be treated with less economic burden.
Abstract
Objective: Pharmacotherapy is considered as an essential element in the treatment of psychotic disorders including schizophrenia. Discontinuation of antipsychotic drugs increases medical use and economic burden. Therefore, maintenance of medication is essential to reduce the social burden caused by schizophrenia and schizophrenia similar psychosis (SSP), and hence, it is important to investigate the rate at which pharmacotherapy is maintained. Therefore, this study aimed to examine the current status of drug compliance using national health insurance data. Methods: This was a retrospective cohort study, which analyzed data from the nationwide insurance claims database. A total of 343,134 patients who were newly diagnosed with schizophrenia and SSP during 2011−2015. The adherence to antipsychotic drugs was assessed by medication possession ratio (MPR) and the risk factors of poor adherence were defined as MPR ＜ 40%. Results: The average of the MPRs was 45.8%, and the proportion of patients with less than 40% of MPR was 50.8%. It was found that female patients, the experience of “general hospital outpatient,” ““ psychiatric hospital admission,” general hospital admission,” and patients receiving “health insurance” showed high risk of having statistically significant low MPR (＜ 40%). Conclusion: In this study, the drug adherence of schizophrenia and SSP patients currently under treatment, as estimated by MPR, was very low. However, it was also found that the MPR was high among patients receiving medical aid, with less medical expenses. Thus, it is possible to consider an institutional mechanism in which schizophrenia and SSP patients can be treated with less economic burden.
참고문헌 (26)
- Sung Joon Cho, "Annual Prevalence and Incidence of Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A National Health Insurance Data-Based Study", PSYCHIATRY INVESTIGATION, 17(1), pp.61~70 (2020), 대한신경정신의학회[DOI]
- Kane JM, "Psychopharmacologic treatment of schizophrenia", Schizophr Bull, 19, pp.287~302 (1993)
- Dixon LB, "Conventional antipsychotic medications for schizophrenia", Schizophr Bull, 21, pp.567~577 (1995)
- Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and metaanalysis", Lancet, 379, pp.2063~2071 (2012)
- Tiihonen J, "Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder : observational follow-up study", BMJ, 333, pp.224~ (2006)
- Geddes J, "Atypical antipsychotics in the treatment of schizophrenia : systematic overview and meta-regression analysis", BMJ, 321, pp.1371~1376 (2000)
- 허정운, "정신병적 장애로 첫 내원한 환자들의 임상 특징과 투약 순응도 및 의료 이용 추이: 예비 연구", 대한조현병학회지, 22(2), pp.35~50 (2019), 대한조현병학회[DOI]
- Weiden PJ, "Cost of relapse in schizophrenia", Schizophr Bull, 21, pp.419~429 (1995)
- Valenstein M, "Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission", Med Care, 40, pp.630~639 (2002)
- Terkelsen KG, "Measuring the costs of schizophrenia. Implications for the post-institutional era in the US", Pharmacoeconomics, 8, pp.199~222 (1995)
- Velligan DI, "Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness", J Clin Psychiatry, 70(Suppl 4), pp.1~46 (2009)
- Morken G, "Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia", BMC Psychiatry, 8, pp.32~ (2008)
- Casey DE, "Metabolic issues and cardiovascular disease in patients with psychiatric disorders", Am J Med, 118(Suppl 2), pp.15S~22S (2005)
- 장성만, "Economic Burden of Schizophrenia in South Korea", Journal of Korean Medical Science, 23(2), pp.167~175 (2008), 대한의학회
- van Os J, "Schizophrenia", Lancet, 374, pp.635~645 (2009)
- Chien IC, "Prevalence and incidence of schizophrenia among National Health Insurance enrollees in Taiwan, 1996-2001", Psychiatry Clin Neurosci, 58, pp.611~618 (2004)
- Wu EQ, "Annual prevalence of diagnosed schizophrenia in the USA : a claims data analysis approach", Psychol Med, 36, pp.1535~1540 (2006)
- 조맹제, "Prevalence and Correlates of DSM-IV Mental Disorders in South Korean Adults: The Korean Epidemiologic Catchment Area Study 2011", PSYCHIATRY INVESTIGATION, 12(2), pp.164~170 (2015), 대한신경정신의학회[DOI]
- The survey of mental disorders in Korea 2016, "Hong JP", Ministry of Health and Welfare, ~ (2016)
- Kim J, "Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009-2016 : a nationwide study", Sci Rep, 8, pp.3133~ (2018)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Lang K, "Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics", Psychiatr Serv, 61, pp.1239~1247 (2010)
- 박종익, "정신질환에 대한 사회적 편견", 신경정신의학, 55(4), pp.299~309 (2016), 대한신경정신의학회[DOI]
- 김재훈, "정신장애 유형에 따른 편견과 차별 - 사례를 활용한 대학생 조사 결과-", 정신건강과 사회복지, (37), pp.35~64 (2011), 한국정신건강사회복지학회
- 전덕인, "정신분열병 환자에서 정신병의 비치료 기간의 임상적 관련변인", 신경정신의학, 43(4), pp.401~406 (2004), 대한신경정신의학회
- Chon MW, "Factors contributing to the duration of untreated prodromal positive symptoms in individuals at ultra-high risk for psychosis", Schizophr Res, 162, pp.64~66 (2015)